title: KHA-CARI commentary on the KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease.
authors.affiliation: Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand; Cochrane Renal Group, Sydney, Australia.
authors.forename: Suetonia C
authors.initials: SC
authors.lastname: Palmer
authors.forename: Giovanni F M
authors.initials: GF
authors.lastname: Strippoli
authors.forename: Jonathan C
authors.initials: JC
authors.lastname: Craig
mesh_terms: D000328:Adult; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D002648:Child; D000069438:Ezetimibe / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D050356:Lipid Metabolism / Q000187:drug effects*; D009398:Nephrology / Q000379:methods / Q000592:standards*; D017410:Practice Guidelines as Topic; D051436:Renal Insufficiency, Chronic / Q000188:drug therapy* / Q000378:metabolism*
chemical_list: D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000069438:Ezetimibe